$ABEO
ABEONA THERAPEUTICS INC.

2017 Q2 Form 10-Q Financial Statement

#000114420417043141 Filed on August 14, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2016 Q4 2016 Q2
Revenue $217.0K $260.0K $214.0K
YoY Change 1.4% 18.18% -23.57%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.640M $2.800M $3.730M
YoY Change -29.22% -34.12% 1.63%
% of Gross Profit
Research & Development $5.808M $3.040M $3.018M
YoY Change 92.45% 46.86% 394.75%
% of Gross Profit
Depreciation & Amortization $207.0K $250.0K $181.0K
YoY Change 14.36% 66.67% 39.23%
% of Gross Profit
Operating Expenses $5.808M $6.090M $3.018M
YoY Change 92.45% -5.87% -31.56%
Operating Profit -$8.440M -$6.715M
YoY Change 25.69%
Interest Expense $160.0K -$1.170M $10.00K
YoY Change 1500.0% -129.92% 0.0%
% of Operating Profit
Other Income/Expense, Net $161.0K $12.00K
YoY Change 1241.67%
Pretax Income -$8.280M -$7.000M -$6.700M
YoY Change 23.58% 199.15% 63.02%
Income Tax
% Of Pretax Income
Net Earnings -$8.279M -$7.000M -$6.703M
YoY Change 23.51% 199.15% 63.09%
Net Earnings / Revenue -3815.21% -2692.31% -3132.24%
Basic Earnings Per Share
Diluted Earnings Per Share -$205.6K -$184.6K -$204.4K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2016 Q4 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $58.30M $69.10M $34.30M
YoY Change 69.97% 72.32% 12.83%
Cash & Equivalents $58.30M $69.14M $34.30M
Short-Term Investments
Other Short-Term Assets $900.0K $200.0K $200.0K
YoY Change 350.0% -33.33% 0.0%
Inventory
Prepaid Expenses
Receivables $100.0K $100.0K $100.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $59.30M $69.42M $34.60M
YoY Change 71.39% 70.99% 11.61%
LONG-TERM ASSETS
Property, Plant & Equipment $700.0K $721.0K $600.0K
YoY Change 16.67% 80.25% 500.0%
Goodwill $32.47M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $100.0K $100.0K
YoY Change 0.0% 0.0%
Total Long-Term Assets $37.36M $41.64M $39.60M
YoY Change -5.66% 5.41% -13.73%
TOTAL ASSETS
Total Short-Term Assets $59.30M $69.42M $34.60M
Total Long-Term Assets $37.36M $41.64M $39.60M
Total Assets $96.66M $111.1M $74.20M
YoY Change 30.27% 38.65% -3.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.617M $3.694M $2.100M
YoY Change 72.24% 310.44% 61.54%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.219M $8.296M $8.700M
YoY Change -51.51% 453.07% 357.89%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.400M $3.700M $4.000M
YoY Change -15.0% -66.06% -73.51%
Total Long-Term Liabilities $3.400M $3.700M $4.000M
YoY Change -15.0% -66.06% -73.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.219M $8.296M $8.700M
Total Long-Term Liabilities $3.400M $3.700M $4.000M
Total Liabilities $7.581M $11.96M $12.70M
YoY Change -40.31% -2.76% -25.29%
SHAREHOLDERS EQUITY
Retained Earnings -$346.0M -$332.5M
YoY Change
Common Stock $435.1M $431.6M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $89.08M $99.10M $61.50M
YoY Change
Total Liabilities & Shareholders Equity $96.66M $111.1M $74.20M
YoY Change 30.27% 38.65% -3.51%

Cashflow Statement

Concept 2017 Q2 2016 Q4 2016 Q2
OPERATING ACTIVITIES
Net Income -$8.279M -$7.000M -$6.703M
YoY Change 23.51% 199.15% 63.09%
Depreciation, Depletion And Amortization $207.0K $250.0K $181.0K
YoY Change 14.36% 66.67% 39.23%
Cash From Operating Activities -$4.980M -$3.390M -$3.110M
YoY Change 60.13% 18.12% 66.31%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$20.00K -$120.0K
YoY Change -91.67% -92.59%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$10.00K -$20.00K -$120.0K
YoY Change -91.67% -92.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 90.00K 41.37M 150.0K
YoY Change -40.0% -99.38%
NET CHANGE
Cash From Operating Activities -4.980M -3.390M -3.110M
Cash From Investing Activities -10.00K -20.00K -120.0K
Cash From Financing Activities 90.00K 41.37M 150.0K
Net Change In Cash -4.900M 37.96M -3.080M
YoY Change 59.09% -1308.92% -113.71%
FREE CASH FLOW
Cash From Operating Activities -$4.980M -$3.390M -$3.110M
Capital Expenditures -$10.00K -$20.00K -$120.0K
Free Cash Flow -$4.970M -$3.370M -$2.990M
YoY Change 66.22% 29.62% 59.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8384000 USD
CY2016Q4 us-gaap Goodwill
Goodwill
32466000 USD
CY2017Q2 us-gaap Other Assets
OtherAssets
66000 USD
CY2016Q4 us-gaap Other Assets
OtherAssets
66000 USD
CY2017Q2 us-gaap Assets
Assets
96659000 USD
CY2016Q4 us-gaap Assets
Assets
111058000 USD
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
403000 USD
CY2017Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
434674000 USD
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
403000 USD
CY2017Q2 us-gaap Royalty Revenue
RoyaltyRevenue
67000 USD
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3617000 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3694000 USD
CY2017Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
602000 USD
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
602000 USD
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4219000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8296000 USD
CY2017Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3362000 USD
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3664000 USD
CY2017Q2 us-gaap Liabilities
Liabilities
7581000 USD
CY2016Q4 us-gaap Liabilities
Liabilities
11960000 USD
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q2 us-gaap Licenses Revenue
LicensesRevenue
150000 USD
CY2016Q2 us-gaap Licenses Revenue
LicensesRevenue
150000 USD
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-345999000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-332473000 USD
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
89078000 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
99098000 USD
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
96659000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
111058000 USD
us-gaap Licenses Revenue
LicensesRevenue
301000 USD
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
431168000 USD
us-gaap Licenses Revenue
LicensesRevenue
301000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
102000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
148000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
403000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
449000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8006000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4873000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5664000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8096000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
457000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
355000 USD
us-gaap Costs And Expenses
CostsAndExpenses
14127000 USD
us-gaap Costs And Expenses
CostsAndExpenses
13324000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-13724000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-12875000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
203000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
631000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-8279000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-6703000 USD
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40270879 shares
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32784123 shares
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
85000 USD
CY2016Q2 us-gaap Royalty Revenue
RoyaltyRevenue
64000 USD
CY2017Q2 us-gaap Sales Revenue Net
SalesRevenueNet
217000 USD
CY2016Q2 us-gaap Sales Revenue Net
SalesRevenueNet
214000 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5808000 USD
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3018000 USD
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2642000 USD
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3730000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-77000 USD
CY2017Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
207000 USD
CY2016Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
181000 USD
CY2017Q2 us-gaap Costs And Expenses
CostsAndExpenses
8657000 USD
CY2016Q2 us-gaap Costs And Expenses
CostsAndExpenses
6929000 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8440000 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6715000 USD
CY2017Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
164000 USD
CY2016Q2 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
13000 USD
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
161000 USD
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
198000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
628000 USD
us-gaap Net Income Loss
NetIncomeLoss
-13526000 USD
us-gaap Net Income Loss
NetIncomeLoss
-12247000 USD
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40262824 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32763568 shares
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40138000 USD
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34303000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2735000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2977000 USD
abeo Allocated Share Based Compensation Expense Restricted Stock
AllocatedShareBasedCompensationExpenseRestrictedStock
686000 USD
abeo Allocated Share Based Compensation Expense Restricted Stock
AllocatedShareBasedCompensationExpenseRestrictedStock
2879000 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-27000 USD
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-3000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
712000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-109000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
46000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1230000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-591000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-302000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-301000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10839000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5632000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
84000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
353000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-84000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-353000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
0 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
150000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
85000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
150000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-10838000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5835000 USD
CY2017Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1492000 USD
CY2017Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1243000 USD
CY2017Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000 USD
CY2017Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
84000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-5247000 USD
CY2017Q2 abeo Payable Due Licensor Current
PayableDueLicensorCurrent
0 USD
CY2016Q4 abeo Payable Due Licensor Current
PayableDueLicensorCurrent
4000000 USD
CY2017Q2 abeo Interest And Other Expense
InterestAndOtherExpense
3000 USD
CY2016Q2 abeo Interest And Other Expense
InterestAndOtherExpense
1000 USD
abeo Interest And Other Expense
InterestAndOtherExpense
5000 USD
abeo Interest And Other Expense
InterestAndOtherExpense
3000 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
4000000 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0 USD
abeo Licensed Technology
LicensedTechnology
127000 USD
abeo Licensed Technology
LicensedTechnology
0 USD
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
95706000 USD
CY2016Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
2.85
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40286332 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40254457 shares
CY2017Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
173000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
346000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
346000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
346000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
346000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
2593000 USD
CY2017Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
158000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
361000 USD
CY2016Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
146000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
291000 USD
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"> (5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Litigation&#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"></font></b>&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">We are not currently subject to any material legal proceedings.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Files In Submission

Name View Source Status
0001144204-17-043141-index-headers.html Edgar Link pending
0001144204-17-043141-index.html Edgar Link pending
0001144204-17-043141.txt Edgar Link pending
0001144204-17-043141-xbrl.zip Edgar Link pending
abeo-20170630.xml Edgar Link completed
abeo-20170630.xsd Edgar Link pending
abeo-20170630_cal.xml Edgar Link unprocessable
abeo-20170630_def.xml Edgar Link unprocessable
abeo-20170630_lab.xml Edgar Link unprocessable
abeo-20170630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v472343_10q.htm Edgar Link pending
v472343_ex31-1.htm Edgar Link pending
v472343_ex31-2.htm Edgar Link pending
v472343_ex32-1.htm Edgar Link pending
v472343_ex32-2.htm Edgar Link pending